MedPath

Recursion Pharmaceuticals

Recursion Pharmaceuticals logo
🇺🇸United States
Ownership
Public
Established
2013-11-05
Employees
500
Market Cap
$2.1B
Website
http://www.recursion.com
Introduction

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Clinical Trials

8

Active:2
Completed:2

Trial Phases

2 Phases

Phase 1:2
Phase 2:4

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 2
4 (66.7%)
Phase 1
2 (33.3%)

A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer

Phase 1
Recruiting
Conditions
Unresectable
Locally Advanced
Metastatic Cancers
Relapsed/Refractory Lymphomas
Interventions
First Posted Date
2024-11-07
Last Posted Date
2025-04-02
Lead Sponsor
Recursion Pharmaceuticals Inc.
Target Recruit Count
85
Registration Number
NCT06678659
Locations
🇺🇸

City of Hope, Duarte, California, United States

🇺🇸

Cleveland Clinic, Cleveland, Ohio, United States

🇺🇸

SCRI Oncology Partners - PPDS, Nashville, Tennessee, United States

and more 1 locations

The Clostridioides Difficile Trial of REC-3964

Phase 2
Terminated
Conditions
Recurrent Clostridioides Difficile Infection
Interventions
First Posted Date
2024-08-05
Last Posted Date
2025-06-12
Lead Sponsor
Recursion Pharmaceuticals Inc.
Target Recruit Count
3
Registration Number
NCT06536465
Locations
🇺🇸

GANJ - Toms River - Ocean Family Gastroenterology, Toms River, New Jersey, United States

🇺🇸

Southern Star Research Institute, LLC, San Antonio, Texas, United States

A Study of REC-4881 in Participants with Cancers Which Have an AXIN1 or APC Mutation

Phase 2
Active, not recruiting
Conditions
AXIN1 Gene Mutation
APC Gene Mutation
Solid Tumor
Interventions
First Posted Date
2023-08-23
Last Posted Date
2024-11-29
Lead Sponsor
Recursion Pharmaceuticals Inc.
Target Recruit Count
60
Registration Number
NCT06005974
Locations
🇺🇸

Sharp Memorial Hospital, San Diego, California, United States

🇺🇸

Sansum Clinic, Santa Barbara, California, United States

🇺🇸

Rocky Mountain Cancer Centers, Denver, Colorado, United States

and more 10 locations

Evaluate REC-4881 in Patients With FAP

Phase 1
Recruiting
Conditions
Familial Adenomatous Polyposis
Interventions
Drug: Placebo
First Posted Date
2022-09-23
Last Posted Date
2025-04-29
Lead Sponsor
Recursion Pharmaceuticals Inc.
Target Recruit Count
67
Registration Number
NCT05552755
Locations
🇺🇸

Mayo Clinic - Scottsdale, Scottsdale, Arizona, United States

🇺🇸

Del Sol Research Management, Tucson, Arizona, United States

🇺🇸

Medical Associates Research Group, San Diego, California, United States

and more 14 locations

Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

Phase 2
Recruiting
Conditions
Neurofibromatosis Type 2
Interventions
Drug: Placebo
First Posted Date
2021-11-23
Last Posted Date
2024-03-01
Lead Sponsor
Recursion Pharmaceuticals Inc.
Target Recruit Count
92
Registration Number
NCT05130866
Locations
🇺🇸

House Institute, Los Angeles, California, United States

🇺🇸

University of California Los Angeles, Los Angeles, California, United States

🇺🇸

Children's National Hospital, Washington, District of Columbia, United States

and more 11 locations
  • Prev
  • 1
  • 2
  • Next

News

Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia

Recursion Pharmaceuticals acquired full rights to REV102, a potential first-in-class oral ENPP1 inhibitor for hypophosphatasia (HPP), from joint venture partner Rallybio for up to $25 million.

MIT and Recursion Release Boltz-2: Open-Source AI Model Achieves 1000x Speed Boost in Drug Discovery Screening

MIT and Recursion have released Boltz-2, the first open-source biomolecular co-folding model that jointly predicts 3D complex structures and molecular binding affinity with unprecedented speed and precision.

Valinor Discovery Emerges from Stealth with AI Platform to Simulate Drug Efficacy Before Clinical Trials

• Valinor Discovery has launched an AI-powered platform that simulates patient responses to therapies before clinical testing, with initial applications in oncology and plans to release its first model within six months. • The company is generating proprietary longitudinal datasets that integrate multi-omics data with clinical assay results from the same patients, addressing the critical gap in high-quality clinical data for translatable biological models. • Strategic partnerships with Helmholtz Munich and Stanford Medicine will establish benchmarking standards for perturbation models and evaluate compounds targeting Alzheimer's disease, while a collaboration with Latch Bio provides no-code access to the platform.

Insilico Medicine Secures $123 Million Series E Funding to Advance AI-Driven Drug Discovery Pipeline

Insilico Medicine closed an oversubscribed Series E financing round totaling $123 million, led by Value Partners Group, to advance its AI-driven drug discovery platform and clinical pipeline.

Recursion's REC-4881 Shows 30% Polyp Reduction in FAP Patients in Phase 1b/2 Trial

Recursion's MEK 1/2 inhibitor REC-4881 demonstrated a median reduction of over 30% in total polyp burden after 12 weeks in patients with familial adenomatous polyposis (FAP), a rare hereditary colorectal cancer syndrome.

Recursion Licenses HealthVerity's Real-World Data to Transform Clinical Trial Design and Analytics

• Recursion has licensed HealthVerity's real-world data covering 340 million US lives to enhance clinical trial design, patient population insights, and operational workflows through its Recursion OS platform. • The partnership aims to industrialize clinical development by integrating privacy-compliant data into AI/ML models, potentially reducing costs and accelerating novel therapeutic development through data-driven decision-making. • HealthVerity's approach ensures HIPAA compliance while providing comprehensive patient journey insights that support clinical development, regulatory submissions, and post-market studies across the healthcare ecosystem.

FDA Announces Shift from Animal Testing to AI Models, Boosting Recursion Pharmaceuticals Stock 20%

The FDA announced plans to replace animal testing with AI models and other human-relevant methods for drug development, initially focusing on monoclonal antibodies before expanding to other drug types.

Recursion and Enamine Launch AI-Powered Compound Libraries to Accelerate Drug Discovery

Recursion Pharmaceuticals and Enamine have created 10 enriched screening libraries containing over 15,000 newly synthesized compounds targeting 100 key drug targets in challenging biological areas.

Recursion Doses First Patient in Phase 1 Trial of REC-3565 for Relapsed B-cell Lymphomas

Recursion has initiated the EXCELERIZE Phase 1 clinical trial of REC-3565, a selective MALT1 inhibitor designed to treat relapsed or refractory B-cell lymphomas.

Recursion-Exscientia Merger Signals New Era in AI-Driven Drug Discovery

• Recursion Pharmaceuticals and Exscientia have completed a landmark $700 million merger, marking the largest AI-focused life sciences deal to date and combining complementary capabilities in biological and chemical AI platforms. • The merged entity now boasts 10 programs in development and significant partnerships with pharmaceutical giants Sanofi and Roche, with their most advanced program targeting cerebral cavernous malformation in Phase 2. • Industry experts predict this merger will catalyze more AI-focused acquisitions in pharma, as companies seek to fully integrate artificial intelligence into traditional drug development processes.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.